🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 48301N203 (prev. 48301N104 )
- IPO
- 9/16/2024 · $4.00/share
Business: Kairos Pharma, Ltd. Is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
Notes: August 21, 2026 -- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number of 48301N203.
Company Contact
- CEO
- John S. Yu
- CFO
- Doug Samuelson
- Headquarters
- 2355 Westwood Blvd., #139, Los Angeles CA 90064
- Phone
- 310-948-2356
- Investor Relations
- Louie Toma · investors@kairospharma.com